IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Application of GUILLAUME, et al. Examiner:

Not Yet Known

Art Unit:

Not Yet Known

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria VA 22313, on

Application No.: 10/823,142

Filed:

April 13, 2004

Title:

METHOD FOR OBTAINING MASTOCYTE LINES FROM PIG TISSUES AND FOR PRODUCING

HEPARIN-TYPE MOLECULES

Jonas Pierre

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID DISCLOSURES

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sirs:

In response to the "Reply To Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Disclosures", which was mailed April 8, 2005, and which indicated that the content of the computer readable form of the Sequence Listing does not comply with the requirements. Applicants submit herewith a substitute computer readable form of the Sequence Listing.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 18-1982. Two (2) duplicate copies of this sheet are enclosed.

Respectfully submitted,

Joel B. German, Reg. No., 48,676

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3444 Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0009 US NP



Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS

O. Box 1450.

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/823,142

04/13/2004

Jean-Marc Guillaume

FRA V2003/0009 US NP
CONFIRMATION NO. 4542

FORMALITIES LETTER

OC00000015693815

005487 ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. ROUTE 202-206 MAIL CODE: D303A BRIDGEWATER, NJ 08807

Date Mailed: 04/08/2005

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

To Download Patentin Software, visit http://www.uspto.gov/web/patents/software.htm For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday,
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Office of Initial Patent Examination (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE